Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001388171-12-000002
Filing Date
2012-07-27
Accepted
2012-07-27 16:17:27
Documents
1
Group Members
CAXTON CORPCXSYNTA LLCKOVNER 2011-A INVESTMENT TRUSTKOVNER 2011-B INVESTMENT TRUSTKOVNER 2011-C INVESTMENT TRUSTKOVNER 2011-D INVESTMENT TRUSTKOVNER 2012-A SYNTA INVESTMENT TRUSTKOVNER 2012-B SYNTA INVESTMENT TRUSTKOVNER 2012-C SYNTA INVESTMENT TRUSTKOVNE

Document Format Files

Seq Description Document Type Size
1 SC 13D - - SYNTA PHARMACEUTICALS AMEND 5 synta13damd5.txt SC 13D/A 30638
  Complete submission text file 0001388171-12-000002.txt   32470
Mailing Address
Business Address 45 HARTWELL AVE LEXINGTON MA 02421 781-274-8200
SYNTA PHARMACEUTICALS CORP (Subject) CIK: 0001157601 (see all company filings)

EIN.: 000000000
Type: SC 13D/A | Act: 34 | File No.: 005-82674 | Film No.: 12990853
SIC: 2834 Pharmaceutical Preparations

Mailing Address 731 ALEXANDER ROAD BUILDING 2 PRINCETON NJ 08540
Business Address 731 ALEXANDER ROAD BUILDING 2 PRINCETON NJ 08540 609-419-1800
CxSynta LLC (Filed by) CIK: 0001388171 (see all company filings)

EIN.: 020604347 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A